Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection

Expert Opinion on Drug Delivery

Volumn 5, Issue 12, 2008, Pages 1313-1321

  Chang, Zhi Yang ^a   Chiang, Chiao Hsi ^a   Lu, Da Wen ^b   Yeh, Ming Kung ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Blood brain (retina) barrier; Drug delivery system; Erythropoiesis; Erythropoietin; Fusion protein; Glycoengineering; Microencapsulation; Nano micro particles; Neuroprotection; PEGylation

Indexed keywords

ANGIOPEPTIN; APTAMER; COPOLYMER; DIMER; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; DRUG CARRIER; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; HYALURONIC ACID; IMMUNOGLOBULIN FC FRAGMENT; INTERFERON; LEUPLIN DEPOT; LEUPRORELIN; LIPOSOME; MACROGOL; MONOMER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHYTOSTEROL; POLYGLACTIN; POLYLACTIC ACID; POLYLYSINE; POLYMER; POLYSACCHARIDE; POLYSORBATE 20; RECOMBINANT ERYTHROPOIETIN; REPOTIN; SOMATULINE DEPOT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANEMIA; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; ERYTHROPOIESIS; GLAUCOMA; HEPATITIS C; HUMAN; HYDROPHILICITY; MALIGNANT NEOPLASTIC DISEASE; MICROENCAPSULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN DEGRADATION; REVIEW; TREATMENT DURATION; TUMOR XENOGRAFT;

ANEMIA; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 58149186702     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802544159     Document Type: Review

References (73)

1. Kendall RG. Erythropoietin. Clin Lab Haematol 2001;23:71-80
2. Dube S, Fisher JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem 1988;263:17516-21
3. Elliott S, Lorenzini T, Chang D, et al. Mapping of the active site of recombinant human erythropoietin. Blood 1997;89:493-502
4. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and bera differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89
5. Jelkmann W. Recombinant EPO production - points the nephrologist should know. Nephrol Dial Transplant 2007;22:2749-53
6. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21
7. Siren AL, Ehrenreich H. Erythropoietin - a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-84
8. Tsai JC, Song BJ, Wu L, et al. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007;16:567-71
9. Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuro protective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury FASEB J 2005;19:1701-3
10. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007;48:1212-8
11. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-92
12. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 2000;17:1159-67
13. Michael M, Hans K, Gerhard W, er al. Microencapsulation of rh-erythropoietin, using biodegradable poty(D,L-lactide-co-glycolide) protein stability and the effects of stabilizing excipients. Eur J Pharm Biopharm 1997;43:29-36
14. Bittner B, Morlock M, Koll H, et al. Recombinant human erythropoietin (rhEPO) loaded poty(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics. Eur J Pharm Biopharm 1998;45:295-305
15. Morlock M, Kissel T, Li YX, et al. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in vitro release properties. J Control Rel 1998;56:105-15
16. Pistel KF, Bittner B, Kott H, et al. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: influence of encapsulation technique and polymer composition on particle characteristics. J Control Release 1999;59:309-25
17. Myung JK, Sun JK, Oh RK. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid. US7276251B2;2007
18. Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol 2005;18:381-7
19. Chiang CH, Yeh MK. Contribution of poly(amino acids) to advances in pharmaceutical biotechnology. Curr Pharm Biotechnol 2003;4:323-30
20. Yeh MK, Chen JL, Chiang CH, et al. The preparation of sustained release erythropoietin microparticle. J Microencapsul 2007;24:82-93
21. Stephen EZ, Paul AB, Howard B, et al. Composition for sustained release of non-aggregated erythropoietin. US5716644;1998
22. Herberger J, Murphy K, Munyakazi L, et al. Carbon dioxide extraction of residual solvents in poly(lactide-co-glycolide) microparticles. J Control Release 2003;90:181-95
23. Nguyen XC, Herberger JD, Burke PA. Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa. Pharm Res 2004;21:507-14
24. Burke PA, Klumb LA, Herberger JD, et al. Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. Pharm Res 2004;21:500-6
25. Moriya H, Maitani Y, Shimoda N, et al. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm Res 1997;14:1621-8
26. Ulrich H, Trujillo CA, Nery AA, Alves JM, Majumder P, Resende RR, et al. DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb Chem High Throughput Screen 2006;9:619-32
27. Lukyanov AN, Elbayoumi TA, Chakilam AR, et al. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Rel 2004;100:135-44
28. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-72
29. Healy JM, Lewis SD, Kurz M, et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 2004;21:2234-46
30. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 2006;103:6315-20
31. Shinjo K, Takeshita A, Higuchi M, et al. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flow-cytometric assay. Br J Haematol 1997;96:551-8
32. Pang IH, Zeng H, Fleenor DL, et al. Pigment epithelium-derived factor protects retinal ganglion cells. BMC Neurosci 2007;8:11
33. Csete M, Rodriguez L, Wilcox M, et al. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci Lett 2004;359:124-6
34. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-40
35. Josef B, Bernd H, Hans PJ. Erythropoietin conjugates. US6340742B1;2002
36. Pascal SB. Erythropoietin conjugates. US6583272B1;2003
37. Jolling K, Perez Ruixo JJ, Hemeryck A, et al. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005;24:465-75
38. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5
39. Qi XR, Mai tani Y, Nagai T, et al. Comparative pharmacokinetics and antitumor efficacy of doxorubicin encapsulated in soybean-derived sterols and poly(ethylene glycol) liposomes in mice. Int J Pharm 1997;146:31-9
40. Sytkowski AJ, Lunn ED, Davis KL, et al. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998;95:1184-8
41. Sytkowski AJ, Lunn ED, Risinger MA, et al. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274:24773-8
42. Dalle B, Henri A, Rouyer-Fessard P, et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo Blood 2001;97:3776-82
43. Battaglia A, Fattorossi A, Pierelli L, et al. The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis. Exp Hematol 2000;28:490-8
44. Lee DE, Oh MS, Chung BS, et al. Fusion protein having enhanced in vivo activity of erythropoietin. US7098318;2006
45. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101:9763-8
46. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl 1):3-10
47. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics; of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
48. Sugasawa K, Deguchi J, Okami T, et al. Immunocytochemical analyses of distributions of Na, K-ATPase and GLUT1, insulin and transferrin receptors in the developing retinal pigment epithelial cells. Cell Struct Funct 1994;19:21-8
49. Dehouck B, Fenart L, Dehouck MP, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997;138:877-89
50. Coloma MJ, Lee HJ, Kurihara A, et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 2000;17:266-74
51. Boado RJ, Zhang Y, Xia CF, et al. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem 2007;18:447-55
52. Pardridge WM, Kang YS, Buciak JL. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood brain barrier in vivo using vector-mediated peptide drug delivery. Pharm Res 1994;11:738-46
53. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000;97:7567-72
54. Spandou E, Papadopoulou Z, Soubasi V, et al. Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in rats. Brain Res 2005;1045:22-30
55. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-7
56. Viviani B, Bartesaghi S, Corsini E, et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 2005;93:412-21
57. Ehrenreich H, Timner W, Siren AL. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ ischemia. Transfus Apher Sci 2004;31:39-44
58. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-805
59. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9
60. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998;15:576-82
61. Chekhonin VP, Zhirkov YA, Gurina OI, et al. PEGylated immunoliposomes directed against brain astrocytes. Drug Deliv 2005;12:1-6
62. Gaillard PJ, Voorwinden LH, Nielsen JL, et al. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci 2001;12:215-22
63. Shoge K, Mishima HK, Mukai S, et al. Rat retinal ganglion cells culture enriched with the magnetic cell sorter. Neurosci Lett 1999;259:111-4
64. Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-16
65. Toimela T, Maenpaa H, Mannerstrom M, et al. Development of an in vitro blood-brain barrier model - cytotoxicity of mercury and aluminum. Toxicol Appl Pharmacol 2004;195:73-82
66. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002;99:10659-64
67. Grunfeld JF, Barhum Y, Blondheim N, et al. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol 2007;204:260-3
68. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31
69. Zhang J, Li Y, Cui Y, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res 2005;1034:34-9
70. Siren AL, Frarelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-9
71. Weishaupt JH, Rohde G, Polking E, et al. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45:1514-22
72. Genc S, Kuralay F, Genc K, et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett 2001;298:139-41
73. Xue YQ, Zhao LR, Guo WP, et al. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 2007;146:1245-58